The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
Yang G, Wang J, Tan L, Munshi M, Liu X, Kofides A, Chen JG, Tsakmaklis N, Demos MG, Guerrera ML, Xu L, Hunter ZR, Che J, Patterson CJ, Meid K, Castillo JJ, Munshi NC, Anderson KC, Cameron M, Buhrlage SJ, Gray NS, Treon SP.
Yang G, et al. Among authors: anderson kc.
Blood. 2021 Nov 18;138(20):1966-1979. doi: 10.1182/blood.2021011405.
Blood. 2021.
PMID: 34132782
Free PMC article.